

**MEMORANDUM** 

## Office of the Academic Senate

Linda Beale, President

To:	CEID Co-Directors Paul Kilgore, Teena Chopra, Marcus Zervos, and Matthew Seeger
CC:	Provost Mark Kornbluh and Interim Dean Wael Sakr
From:	Academic Senate Policy Committee
In Re:	CEID Self-Study and Five-Year Charter
Date:	April 25, 2022
	-

The Policy Committee has reviewed the report presented as a request for a five-year charter for the Center for Emerging and Infectious Diseases (CEID). We are delighted to see that the temporary charter granted on June 30, 2021 enabled CEID to apply for and receive \$4.3 million in funding to expand sequencing of infectious diseases through the CDC Epidemiology and Laboratory Capacity grant and MDHHS for MI-SAPPHIRE.

We have tentatively concluded, as noted in item 7, below, that this center's charter must be approved through the Board of Governor's CIAC-I process, and thus the charter request will need to be referred to the CIAC-I committee prior to returning to Policy. In order for Policy to fully support a charter for CEID as a CIAC-I center, it would be helpful to have additional information not specifically included in the current report, which presumably the CIAC-I committee will also require. The Policy Committee members would appreciate concise and clear responses to the questions in this memorandum as a basis for our ultimate recommendation regarding a full charter for the center.

In this context please also see the attached June 30, 2021 memorandum to Interim Provost Clabo with similar questions Policy raised regarding the initial request for a temporary charter. We continue to have concerns regarding the lack of clarity about administrative positions within the center and the specified leadership plan to handle coordination and disagreements: the description of staff and governance structure on page 11 and pages 14 - 16 is remarkably vague about key responsibilities, as is the organizational chart in Appendix A.

1. Center Activities as contrasted with School of Medicine Activities: The executive summary of the current document provides a discussion of focus and activities of the CEID. These foci and activities appear exceptionally broad, encompassing many of the already-existing activities of the medical school and covered by pre-CEID formation individual grants of the various people listed in the report as CEID participants. This breadth of coverage is included in the statement of mission in Appendix D, which encompasses training, research, community engagement, public health infrastructure, vaccine development, evaluation and deployment, development of tools to facilitate response to outbreaks, use of the laboratories to run revenue-generating lab services, and public service to vulnerable populations. The government affairs summary in Addendum H states that there are three areas of focus: creating laboratory facilities for disease surveillance and research; addressing vaccine hesitance and deployment; and education. The discussion of the global health concentration described in Appendix E is cast as part of the center, but it is an already existing academic program that can only exist within the medical school, with requirements set by the medical school faculty and through the curriculum and degree approval processes of the university. In fact, the materials

indicate that this initiative has been underway since 2019 with an organizational structure within the medical school. Accordingly, it would be helpful if you would delineate the **unique** activities of the CEID and state clearly the relationship between the center and the medical school for the various items in your multi-focused mission statements. Your response should indicate what grants are expected to be sought that would not likely be funded without the connection to the center and make clear what additional value the CEID adds that is not already existent in the medical school.

- 2. <u>Center Laboratories</u>: Part of the appeal of the center is that it will be able to undertake important bench research and also provide valuable genomic sequencing services that bring additional revenues into the university through laboratory services. Yet the report is rather unclear about the existing laboratories and the expected source of funding for, and location of, the center's facilities. See, e.g., the paragraph on page 8 of the executive summary indicating that there is a CLIA certified laboratory and then stating that there is not such a laboratory on the WSU campus. Laboratories require significant budgetary commitments, especially if they are of the quality to deal with infectious diseases. *Please clarify the exact location, type, support and funding separately for each laboratory considered part of the CEID*.
- 3. <u>MOUs</u>. The report mentions a variety of MOUs, but none are attached. *Please clarify whether there are MOUs with the CEID itself or whether this mention is merely a description of the CEID's intent to benefit from existing university or medical school MOUs. If the latter, please explain what unique relationships are expected to exist under the MOUs between the CEID and the MOU partners.*
- 4. <u>Center Advisory Board</u>. The "Advisory/Steering Committee" membership listed on page 4 appears to be the group that shepherded the Bold Moves proposal. At least five of those are also listed as "participating faculty" (p.17) and thus do not bring outside expertise and oversight to the Center. There is mention in the report on page 17 of a plan to establish a center advisory board, which suggests that the earlier listing was indeed an ad hoc group. The outside expertise offered by an advisory board with representation from beyond WSU (and likely also from beyond the Detroit area) is essential to oversight of such a large multi-focused center. *Please provide detailed information on the people who have agreed at this time to serve on the CEID's advisory board*.
- 5. <u>Center Budget</u>: The executive summary mentions that support for CEID includes funding provided by the School of Medicine and space provided by the university but provides no details whatsoever. The charter process requires a comprehensive budget for new centers, but the budget submitted only provides information about the MI-SAPPHIRE budget supporting PI Teena Chopra's sequencing laboratory. *Please provide a detailed actual budget for the year of the temporary charter (i.e., 2021-22) with information about sources and uses of funds and a detailed projected budget for the first 5 years of the full charter that includes all CEID staff positions and compensation expected for those positions in those years as well as all CEID laboratories and other space costs and funding or in-kind support provided by any CEID partners (School of Medicine, Henry Fund Health, or other partners). Please include information about indirect cost recovery/F&A funds.*
- 6. <u>Similar Centers Elsewhere</u>. The executive summary (page 5) notes that the CEID will be the "first such center in an urban setting" in Michigan. *Please provide information on other centers at urban public research universities in the United States or beyond and describe the unique features of the CEID that should result in a national and international reputation for the Center.*
- 7. <u>CIAC Review</u>: Because the report states that there are co-directors from outside the School of

Medicine and also states that there is both School of Medicine funding and university space and facilities support (not to mention the compensation paid to co-director Zervos as Assistant Dean of Global Health), it appears that this center is one that should be reviewed under the Board of Governors statutes by the CIAC-I committee. Our assessment of that will depend in part on the supplemental information provided, but we note that *this complicated and cross-disciplinary center* with multiple focus areas that overlap with university and School of Medicine activities seems to epitomize the kind of center that was intended to undergo scrutiny through the CIAC process.

Linda M. Beale

Linda M. Beale Professor, Law School, and President, Academic Senate

## On behalf of the Policy Committee:

Danielle Aubert, Assoc. Professor, Art & Art History; AAUP-AFT Local 6075 Liaison to Policy Paul Beavers, Librarian and Chair, Budget Committee

Jane Fitzgibbon, Assoc. Professor of Teaching, CFPCA; and Chair, Facilities, Support Services and Technology Committee

Jennifer Lewis, Assoc. Professor, College of Education; and Chair, Curriculum and Instruction Committee

Noreen Rossi, Professor of Internal Medicine, School of Medicine; Vice Chair, Academic Senate; and Chair, Research Committee

Brad Roth, Professor, Political Science and Law; Liaison, Curriculum and Instruction Committee; and Chair, ad hoc Subcommittee on Student Code of Conduct Revisions

Naida Simon, Provost's Office, and Chair, Student Affairs Committee and Elections Committee

Ricardo Villarosa, Coordinator of Student Life, Dean of Students Office; Parliamentarian, Academic Senate; and Liaison, Budget